PART I . We are a biotechnology company focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including LAPC, will be developed. The current generation of our product candidate is referred to as CypCaps. During the year ended April 30, 2024, we determined that research and development ...
Q2 FY2026 — expected 2026-09-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-08-11 | 2025-04-30 | 0001683168-25-005821 | EDGAR | 103K words |
| 2024-08-13 | 2024-04-30 | 0001683168-24-005575 | EDGAR | — |
| 2023-07-31 | 2023-04-30 | 0001683168-23-005175 | EDGAR | — |
| 2022-07-28 | 2022-04-30 | 0001683168-22-005189 | EDGAR | — |
| 2021-08-10 | 2021-04-30 | 0001683168-21-003377 | EDGAR | — |
| 2020-08-13 | 2020-04-30 | 0001683168-20-002680 | EDGAR | — |
| 2019-08-13 | 2019-04-30 | 0001683168-19-002559 | EDGAR | — |
| 2018-07-20 | 2018-04-30 | 0001683168-18-001994 | EDGAR | — |
| 2017-07-27 | 2017-04-30 | 0001683168-17-001881 | EDGAR | — |
| 2016-07-29 | 2016-04-30 | 0001019687-16-007057 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-17 | 2026-01-31 | 0001683168-26-001917 | EDGAR | 30K words |
| 2025-12-18 | 2025-10-31 | 0001683168-25-009259 | EDGAR | — |
| 2025-09-15 | 2025-07-31 | 0001683168-25-006991 | EDGAR | — |
| 2025-03-17 | 2025-01-31 | 0001683168-25-001669 | EDGAR | — |
| 2024-12-13 | 2024-10-31 | 0001683168-24-008709 | EDGAR | — |
| 2024-09-17 | 2024-07-31 | 0001683168-24-006441 | EDGAR | — |
| 2024-03-18 | 2024-01-31 | 0001683168-24-001525 | EDGAR | — |
| 2023-12-15 | 2023-10-31 | 0001683168-23-008889 | EDGAR | — |
| 2023-09-18 | 2023-07-31 | 0001683168-23-006505 | EDGAR | — |
| 2023-03-16 | 2023-01-31 | 0001683168-23-001559 | EDGAR | — |
| 2022-12-14 | 2022-10-31 | 0001683168-22-008428 | EDGAR | — |
| 2022-09-14 | 2022-07-31 | 0001683168-22-006394 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-02 | 0001683168-26-002613 | EDGAR | 12K words |
| 2025-12-05 | 0001683168-25-008947 | EDGAR | — |
| 2025-10-31 | 0001683168-25-007871 | EDGAR | — |
| 2025-09-05 | 0001683168-25-006727 | EDGAR | — |
| 2025-08-18 | 0001683168-25-006274 | EDGAR | — |
| 2025-04-24 | 0001683168-25-002790 | EDGAR | — |
| 2025-02-26 | 0001683168-25-001236 | EDGAR | — |
| 2024-05-23 | 0001683168-24-003796 | EDGAR | — |
| 2024-05-01 | 0001683168-24-002881 | EDGAR | — |
| 2023-11-24 | 0001683168-23-008446 | EDGAR | — |
225 total filings indexed. 193 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001157075 |
| Ticker | PMCB |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | NV |
| Website | https://pharmacyte.com |
| Listed | 2003-09-11 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report